Saghmos Therapeutics reposted this
Saghmos Therapeutics is participating in the 3rd Annual Kidney Virtual Conference hosted by H.C. Wainwright. Please join me on Monday, July 15, 2024 at 11 a.m. ET via live webcast (https://lnkd.in/ez5GFpX6) to learn more about our Phase 3-ready cardiovascular-kidney-metabolic modular, ST-62516. Saghmos is developing ST-62516 for reducing the risk of complications after PCI, a major unmet medical need with no FDA-approved drugs and a multi-billion dollar revenue potential. Stephen Grant, M.D., former Deputy Director of FDA’s Division of Cardiology and Nephrology and Saghmos’ Chief Regulatory Officer and I will be available for 1x1 virtual meetings. Reach out via LinkedIn message to schedule a meeting. A replay of the webcast will be available shortly after the presentation. #CKM #CardiovascularKidneyMetabolic #Cardiorenal #AcuteKidneyInjury #AKI #PCI #CVRM #ChronicKidneyDisease #CKD #Dialysis